skip to main content
Idioma:

Revisiting the Development of Vaccines Against Pathogenic Leptospira : Innovative Approaches, Present Challenges, and Future Perspectives

Barazzone, Giovana C ; Teixeira, Aline F ; Azevedo, Bruna O P ; Damiano, Deborah K ; Oliveira, Marcos P ; Nascimento, Ana L T O ; Lopes, Alexandre P Y

Frontiers in immunology, 2022-01, Vol.12, p.760291-760291 [Periódico revisado por pares]

Switzerland: Frontiers Media S.A

Texto completo disponível

Citações Citado por
  • Título:
    Revisiting the Development of Vaccines Against Pathogenic Leptospira : Innovative Approaches, Present Challenges, and Future Perspectives
  • Autor: Barazzone, Giovana C ; Teixeira, Aline F ; Azevedo, Bruna O P ; Damiano, Deborah K ; Oliveira, Marcos P ; Nascimento, Ana L T O ; Lopes, Alexandre P Y
  • Assuntos: Bacterial Vaccines - immunology ; Bacterial Vaccines - pharmacology ; development of vaccine ; human leptospirosis vaccine ; Humans ; Immunology ; Leptospira ; Leptospira - immunology ; leptospirosis ; Leptospirosis - prevention & control ; vaccine ; Vaccine Development
  • É parte de: Frontiers in immunology, 2022-01, Vol.12, p.760291-760291
  • Notas: ObjectType-Article-2
    SourceType-Scholarly Journals-1
    ObjectType-Feature-3
    content type line 23
    ObjectType-Review-1
    These authors share senior authorship
    Edited by: Bertrand Kaeffer, Institut National de recherche pour l’agriculture, l’alimentation et l’environnement (INRAE), France
    These authors have contributed equally to this work
    Reviewed by: Yung-Fu Chang, Cornell University, United States; Jennifer Wilson-Welder, United States Department of Agriculture (USDA), United States
    This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
  • Descrição: Human vaccination against leptospirosis has been relatively unsuccessful in clinical applications despite an expressive amount of vaccine candidates has been tested over years of research. Pathogenic encompass a great number of serovars, most of which do not cross-react, and there has been a lack of genetic tools for many years. These obstacles have hampered the understanding of the bacteria's biology and, consequently, the identification of an effective antigen. Thus far, many approaches have been used in an attempt to find a cost-effective and broad-spectrum protective antigen(s) against the disease. In this extensive review, we discuss several strategies that have been used to develop an effective vaccine against leptospirosis, starting with -inactivated bacterin, proteins identified in the genome sequences of pathogenic , including reverse vaccinology, plasmid DNA, live vaccines, chimeric multi-epitope, and toll- and nod-like receptors agonists. This overview should be able to guide scientists working in the field to select potential antigens and to choose the appropriate formulation to administer the candidates.
  • Editor: Switzerland: Frontiers Media S.A
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.